Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report


Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK

Received 18 February 2004; revised 11 June 2004; accepted 24 June 2004

Introduction

Cardiovascular magnetic resonance (CMR) is established in clinical practice for the diagnosis and management of diseases of the cardiovascular system. However, current guidelines for when this technique should be employed in clinical practice have not been revised since a Task Force report of 1998.1 Considerable technical and practice advances have been made in the intervening years and the level of interest from clinicians in this field is at an unprecedented level. Therefore the aim of this report from a Consensus Panel of established experts in the field of CMR is to update these guidelines. As CMR is a multi-disciplinary technique with international interest, the Consensus Panel was composed of European and American cardiologists and radiologists with major input from members with additional established expertise in paediatric cardiology, nuclear cardiology, magnetic resonance physics and spectroscopy, as well as health economics. The Consensus Panel was originated, approved and funded in its activities by the Working Group on CMR of the European Society of Cardiology and the Society for Cardiovascular Magnetic Resonance.

The Consensus Panel recommendations are based on evidence compiled from the literature and expert experience. If there is insufficient evidence in the literature, this is indicated in the report but usually no recommendations are made under these circumstances. The appropriateness of using CMR is described for the frequent disease entities where imaging information may be warranted. The diagnostic use of CMR will be described in the context of other, competing imaging techniques, with particular emphasis on the differential indications with respect to echocardiography.

The usefulness of CMR in specific diseases is summarized by means of the following classification:

Class I = provides clinically relevant information and is usually appropriate; may be used as first line imaging technique; usually supported by substantial literature.

Class II = provides clinically relevant information and is frequently useful; other techniques may provide similar information; supported by limited literature.

Class III = provides clinically relevant information but is infrequently used because information from other imaging techniques is usually adequate.

Class Inv = potentially useful, but still investigational.

This classification is not meant to equate to AHA/ACC/ESC consensus documents. We have used the classification system that was used for the first consensus report,1 with minor amendments in order to maintain parity with that report so that advances in the field can be readily identified. It should also be noted that the classification system for imaging technologies does not easily marry with that of therapeutic trials because the datasets are smaller, multi-centre trials are unusual and randomized controlled trials are the exception. In addition, the experience worldwide with the clinical applications of CMR is still limited.

It should also be noted that this consensus report reflects opinion at the start of 2004. The rapidly continuing technical and clinical advances in CMR will change the
Outline of CMR techniques

A brief description of the technical aspects of CMR is included here to facilitate understanding of the technical terms used in the clinical part of this report. It is necessarily brief and fuller texts give much greater detail.\textsuperscript{2,3} A key point to understanding clinical CMR is that the interaction required for clinical imaging is at the level of the nucleus, which means that CMR is fundamentally safe and does not interfere with the electron shells involved in chemical binding (particularly in DNA) that can be altered by ionizing radiation such as X-rays. Only atomic nuclei with unpaired spin can exhibit the phenomenon of magnetic resonance as first described in 1946. Although this includes important elements such as carbon, oxygen, sodium, potassium and fluorine, these elements are rarely used for imaging in clinical practice. Phosphorous is used for clinical CMR spectroscopy, but the majority of clinical CMR interrogates the hydrogen nucleus which is abundant in water, fat and other biochemical compounds in the human body.

The hydrogen nucleus (a single proton), behaves as a small spinning magnet which aligns itself parallel to an external magnetic field and precesses about the field in the same way that a spinning top precesses in a gravitational field. The frequency of precession is 63 MHz for a field strength of 1.5 Tesla which is in the radiofrequency range. The ensemble of nuclei in a body region can be excited by radiowaves only at this resonant frequency, which has the effect of rotating the net magnetisation vector by an amount termed the \textit{flip angle}. After this excitation, the net magnetization vector precesses around the direction of the main field, returning to its former position (\textit{relaxation}). Whilst there is a component of magnetization perpendicular to the applied magnetic field, energy is transmitted as a radio signal and this can be received by a receiver coil placed over the chest. The return of the net magnetisation vector to equilibrium has two components: The vector component parallel to the main field returns to equilibrium by interacting with surrounding molecules which is a relatively slow process and is known as \textit{T1 relaxation}. The vector component transverse to the field is more rapid and results from interaction between individual spins, and is termed \textit{T2 relaxation}. CMR images can be weighted to show the distribution of T1 or T2, or just the density of protons. In order to localize the signals coming from the body, additional magnetic fields are required which are switched on and off at appropriate times; these are termed \textit{gradient fields}. An MR image therefore simply represents the spatially resolved signal coming from the relaxing spins.

A CMR scanner has six major components. The magnet, which is usually superconducting, produces the static magnetic field whose strength is measured in Tesla. This field needs to be homogeneous and stable with time, and yet large enough to contain a human body. Resistive \textit{gradient coils} within the bore of the magnet produce the gradient fields, and the currents within these coils are driven by the \textit{gradient amplifiers}. The performance of the gradient system determines how fast magnetic resonance acquisition can be. A \textit{radiofrequency coil} (antenna) is coupled to a \textit{radiofrequency amplifier} to excite the patient with the radiofrequency pulses, and this (or another more localized surface coil) is coupled to the receiver to measure the signals coming from the patient. A computer is required to control the scanner and generate the images. Images are then displayed in static, dynamic (cine) modes or as multi-planar reconstructions.

An MR pulse sequence is a combination of radiofrequency pulses and magnetic gradient field switches, and can be considered as an orchestral score with multiple aspects of the scanner acting in concert and controlled by the scanning computer. For CMR, \textit{spin echo}, \textit{gradient echo}, \textit{steady state free precession} (SSFP) and \textit{echo-planar imaging} (EPI) sequences are the most commonly used for the signal read-out. Spin echo sequences are routinely used for multi-slice anatomical imaging and rapidly moving blood is typically displayed as black, whilst gradient echo and SSFP sequences are used for physiological assessment of function through cine acquisitions, and blood is typically white. Pre-pulses may be added to sequences and these may change the contrast appearances. For example, an \textit{inversion recovery} prepulse is typically used for infarct/viability imaging, where myocardium is nulled to be black, infarct is white and blood is an intermediate grey. With modern scanners, many sequences are now performed during a 4–20 s breath-hold. This reduces image artefacts from respiratory motion. ECG gating is required for most CMR in order to coordinate the acquisition to the correct phases of the cardiac cycle. Some specialized sequences exist which have particular application for the cardiovascular system. CMR angiography (MRA) is usually performed with three-dimensional (3D) coverage of the vessel during a short breath-hold and after intravenous injection of a gadolinium-based contrast agent. Gadolinium has seven unpaired electrons in its outer shell which hastens T1 relaxation, and usually thereby increases the signal in the area of interest. Non-contrast MR angiographic techniques are also sometimes used. Myocardial perfusion CMR follows the effect of a first pass of a bolus of intravenous gadolinium through multiple planes of the myocardium using ultrafast sequences such as Fast Low Angle Shot (FLASH), EPI or SSFP which can allow entire images to be acquired in <200 ms. For coronary CMR, some high resolution acquisitions cannot be completed within a breath-hold, and respiratory motion is reduced by using a \textit{navigator}, whereby the diaphragm (or other interface) is monitored in real-time. In order to study regional myocardial contraction, a sequence called \textit{tagging} may be used, which superimposes a grid of dark lines across the image in diastole. These tags subsequently deform through the cardiac cycle allowing the calculation of regional myocardial strain. Finally, \textit{velocity mapping} is a sequence used to measure velocity and flow in blood vessels or within the heart somewhat.
Congenital heart disease

General aspects

Evaluation of patients with congenital heart disease (CHD) is a significant strength of CMR because 3D contiguous data sets are very effective for the complete depiction of the pathological anatomy of both simple and complex CHD. Moreover, the lack of ionizing radiation is an important consideration when performing sequential studies in children and young adults. However, the clinical use of CMR depends on the age and the clinical condition of the patient. Sedation is required in small children and monitoring is demanding in critically-ill infants. Thus, CMR is usually performed following, and as an adjunct to, transthoracic echocardiography in neonates and infants. In contrast, CMR becomes the first line technique when in older children, in adolescents or adults, in more complex anatomy, or at any age after surgery because body habitus and interposition of scar tissue and lungs become an increasing problem for transthoracic echocardiography.6,7 The need for and duration and risks of diagnostic catheterisation can be minimised by prior use of CMR.6,8 Thus, diagnostic catheterisation is likely to become a one stage process with concurrent interventional procedures. Precise depiction of cardiac and arterial/venous great vessel anatomy using CMR should also decrease the duration and radiation dose associated with interventional procedures. In recent years, dual X-ray/CMR facilities have been proposed for more efficient diagnostic and interventional procedures during a single anaesthesia session.9 Expertise in CMR is highly recommended in centres specialised in the care of patients with congenital heart disease.6

CMR techniques are generally less operator dependent than echocardiography, but a thorough understanding of the anatomic and functional principles of CHD is nevertheless required for a reliable study. This requires experience and training guidelines have been published.10 All parts of the cardiovascular system can be imaged, a feature which makes a CMR evaluation especially useful in complex cases. For a complete CMR examination, the following sequences should be performed:

1. Anatomical images in the transaxial and at least one additional orthogonal plane (sagittal or coronal depending on the case). For thoracic aortic anomalies, additional oblique sections are acquired. Usually these are spin echo acquisitions.
2. Functional information with SSFP sequences in contiguous short axis planes for the evaluation of biventricular function, volumes, and mass.
3. When clinically indicated, measurements of velocity and flow volume in the heart and great vessels/conduits.
4. Gadolinium-enhanced MRA for 3D representation of the thoracic aorta, pulmonary arteries, and veins. For specific indications, it may also be employed for the 3D display of complex cardiovascular anatomy. CMR may be used in the following specific congenital anomalies (see Table 1):

1. Anomalies of the viscero-atrial situs. The viscero-atrial situs (situs solitus, inversus, ambiguus) and malposition of the heart (dextrocardia, levocardia) are easily identified by conventional diagnostic methods. However, in the presence of additional lesions (atrioventricular or ventriculoarterial discordance, anomalous pulmonary or systemic venous connections) difficulties may arise in the definition of the topographic relation of the major cardiac segments. CMR provides anatomical data which is easily related to the surrounding structures of the body,6 and thus provides reliable diagnoses with a sensitivity approaching 100%.11 In patients with complex anomalies, especially in older patients, CMR may be the primary imaging technique so as to maximise non-invasive information prior to catheterisation.

2. Anomalies of the atria and venous anomalies. CMR may be valuable in the assessment and identification of atrial septal defects. Quantification of shunt size (pulmonary to systemic flow ratio) by CMR compares favourably to other imaging techniques and should be considered a primary method.12 The best technique for assessing the interatrial septal morphology is transesophageal echocardiography (TEE).13 In infants, CMR may be used as a second line technique following transthoracic echocardiography. A drawback of echocardiography is the difficulty of evaluating anomalous pulmonary venous return. CMR appears to be the best non-invasive technique for the evaluation of pulmonary veins.14,15 As complete and selective demonstration may not be achieved by echocardiography or X-ray angiography.16 CMR may also be indicated to identify partial anomalous venous return in patients with atrial septal defects.17 CMR may identify atrial septal defect (ASD) or partial anomalous pulmo-
Clinical indications for cardiovascular magnetic resonance

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Indications for CMR in congenital heart disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General indications</strong></td>
<td></td>
</tr>
<tr>
<td>1. Initial evaluation and follow-up of adult congenital heart disease</td>
<td>I</td>
</tr>
<tr>
<td><strong>Specific indications</strong></td>
<td></td>
</tr>
<tr>
<td>1. Assessment of shunt size (Qp/Qs)</td>
<td>I</td>
</tr>
<tr>
<td>2. Anomalies of the viscero-atrial situs</td>
<td></td>
</tr>
<tr>
<td>Isolated situs anomalies</td>
<td>II</td>
</tr>
<tr>
<td>Situs anomalies with complex congenital heart disease</td>
<td>I</td>
</tr>
<tr>
<td>3. Anomalies of the atri and venous return</td>
<td></td>
</tr>
<tr>
<td>Atrial septal defect (secundum and primum)</td>
<td>II</td>
</tr>
<tr>
<td>Anomalous pulmonary venous return, especially in complex anomalies and cor triatriatum</td>
<td>I</td>
</tr>
<tr>
<td>Anomalous systemic venous return</td>
<td>I</td>
</tr>
<tr>
<td>Systemic or pulmonary venous obstruction following intra-atrial baffle repair or correction of anomalous pulmonary venous return</td>
<td>I</td>
</tr>
<tr>
<td>4. Anomalies of the atrioventricular valves</td>
<td></td>
</tr>
<tr>
<td>Anatomic anomalies of the mitral and tricuspid valves</td>
<td>II</td>
</tr>
<tr>
<td>Functional valvular anomalies</td>
<td>II</td>
</tr>
<tr>
<td>Ebstein’s anomaly</td>
<td>II</td>
</tr>
<tr>
<td>Atrioventricular septal defect</td>
<td>II</td>
</tr>
<tr>
<td>5. Anomalies of the ventricles</td>
<td></td>
</tr>
<tr>
<td>Isolated ventricular septal defect</td>
<td>III</td>
</tr>
<tr>
<td>VSD associated with complex anomalies</td>
<td>I</td>
</tr>
<tr>
<td>Ventricular aneurysms and diverticula</td>
<td>II</td>
</tr>
<tr>
<td>Supracristal VSD</td>
<td>I</td>
</tr>
<tr>
<td>Evaluation of right and left ventricular volumes, mass and function</td>
<td>I</td>
</tr>
<tr>
<td>6. Anomalies of the semilunar valves</td>
<td></td>
</tr>
<tr>
<td>Isolated valvular pulmonary stenosis and valvular dysplasia</td>
<td>III</td>
</tr>
<tr>
<td>Supravalvular pulmonary stenosis</td>
<td>II</td>
</tr>
<tr>
<td>Pulmonary regurgitation</td>
<td>I</td>
</tr>
<tr>
<td>Isolated valvular aortic stenosis</td>
<td>III</td>
</tr>
<tr>
<td>Subaortic stenosis</td>
<td>III</td>
</tr>
<tr>
<td>Supravalvular aortic stenosis</td>
<td>I</td>
</tr>
<tr>
<td>7. Anomalies of the arteries</td>
<td></td>
</tr>
<tr>
<td>Malpositions of the great arteries</td>
<td>II</td>
</tr>
<tr>
<td>Post-operative follow-up of shunts</td>
<td>I</td>
</tr>
<tr>
<td>Aortic (sinus Valsalva) aneurysm</td>
<td>I</td>
</tr>
<tr>
<td>Aortic coarctation</td>
<td>I</td>
</tr>
<tr>
<td>Vascular rings</td>
<td>I</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td>III</td>
</tr>
<tr>
<td>Aortopulmonary window</td>
<td>I</td>
</tr>
<tr>
<td>Coronary artery anomalies in infants</td>
<td>Inv</td>
</tr>
<tr>
<td>Anomalous origin of coronary arteries in adults and children</td>
<td>I</td>
</tr>
<tr>
<td>Pulmonary atresia</td>
<td>I</td>
</tr>
<tr>
<td>Central pulmonary stenosis</td>
<td>I</td>
</tr>
<tr>
<td>Peripheral pulmonary stenosis</td>
<td>Inv</td>
</tr>
<tr>
<td>Systemic to pulmonary collaterals</td>
<td>I</td>
</tr>
</tbody>
</table>

CMR may be particularly useful for demonstrating pulmonary venous stenoses or occlusions post-operatively, or after ablation. It is effective for demonstrating stenoses of intra-atrial baffles after repair of transposition of the great arteries. Moreover, systemic venous anomalies (bilateral superior cava, interrupted inferior cava) are correctly identified by CMR.

3. **Anomalies of the atrioventricular connections.** CMR is an excellent technique for defining the morphologic features of each atrium and ventricle. Consequently, it can demonstrate discordant atrioventricular connections and crisscross atrioventricular connections. CMR is also indicated for demonstrating double inlet ventricle, straddling atrioventricular valve, tricuspid atresia, and mitral atresia. Echocardiography is usually employed initially for these abnormalities and CMR is used to supplement this information. CMR is superior to echocardiography for quantifying ventricular volumes in these abnormalities which may be critical for surgical decisions regarding biventricular repair versus the Fontan procedure.

4. **Anomalies of the ventricles.** CMR is highly sensitive and specific for the quantification and detection of ventricular septal defects, and detection and localisation of jets is helpful. However, CMR may add little anatomical information in isolated ventricular septal defect when the diagnosis is already established by echocardiography, except that CMR can readily quantify shunt volume. This may become more relevant if clinicians come to rely on noninvasive diagnostic information prior to surgery. CMR has an important role in depicting ventricular anatomy in complex anomalies such as in tetrology of Fallot, pulmonary atresia, tricuspid atresia, and univentricular hearts. CMR can precisely depict the location of the ventricular septal defect in relation to the great arteries in double outlet ventricles. CMR is the most accurate technique for quantifying left and right ventricular mass and volumes.

5. **Valves.** Echocardiography is the primary imaging modality for defining valve morphology, and estimating valvular regurgitation. However, CMR velocity mapping can quantify the severity of regurgitation in many cases, and this is valuable for sequential monitoring of the severity of pulmonary regurgitation after outflow patch surgery for tetrology of Fallot and after placement of RV to pulmonary artery conduits. Thus, CMR may be useful for decision making on valve replacement. CMR has also been shown to be effective for the morphologic depiction of tricuspid atresia and Ebstein’s anomaly. Moreover, it can provide a precise RV volumetric and functional assessment in these anomalies.

6. **Anomalies of the great arteries and conduits.** CMR is very effective for the evaluation of anomalies of the thoracic aorta. Although 2D echocardiography with Doppler is usually sufficient to diagnose and estimate the haemodynamic severity of coarctation of
the aorta in infants, difficulties may be encountered in older children or adults. Under these circumstances the severity and extent of stenosis including diffuse narrowing of the aortic arch, the collateral circulation as well as the shape and size of the ascending aorta can be demonstrated by CMR. Velocity mapping can estimate the pressure gradient across the coarctation and the volume of collateral flow. Thus, CMR is now regarded as the optimal modality for the evaluation of coarctation of the aorta. CMR is also the procedure of choice for evaluation of coarctation after surgery or angioplasty.

8. **Acquired vascular disease**

CMR is well-established for evaluation of a wide variety of acquired vascular diseases. CMR is particularly useful for vascular lumen imaging with its ability to generate projection angiograms (MRA). These can be generated either with time-of-flight techniques, or with intravenous gadolinium, which has similar pharmacokinetic properties to iodinated X-ray contrast but with the advantage of minimal nephrotoxicity. Consequently, it is well-suited for use in patients with contraindications to X-ray contrast (allergy, renal insufficiency). In addition to angiography, the wide variety of soft tissue con-

---

1944 D.J. Pennell et al.
trast available on CMR (proton density, T1, T2, lipid-saturation) can be applied to vascular imaging to assess features of vessel wall such as haematoma/thrombus, inflammation, and atherosclerotic plaque. In addition to morphologic imaging of blood vessels, velocity mapping can be used to assess and measure the blood flow. Blood velocity and flow can be integrated across the cardiac cycle and the vessel lumen for reliable volume flow measurements (see Table 2).

**Aorta**

For the thoracic and abdominal aorta, CMR accurately displays the size, extent, and shape of aneurysms. Multi-planar imaging is helpful in tortuous segments to evaluate and follow cross-sectional diameters and areas as well as to assess the relationship of the aneurysm to major branch vessels. Both black-blood and white-blood imaging can be used to differentiate patent lumen from intraluminal thrombus. Gadolinium MRA is a necessary adjunct for visualizing any associated branch-vessel occlusive disease or relationship of the aneurysm to smaller vessels.

Flow-sensitive imaging cannot be relied upon in the setting of aneurysmal disease due to the stagnant flow patterns that may be present and gadolinium MRA is more robust. Post-gadolinium T1-weighted CMR, especially with fat saturation, is helpful in identifying areas of peri-aortic inflammation in mycotic aneurysms. Inflammatory abdominal aortic aneurysms can have a thick rind of tissue encircling the anterior and lateral aspects of the aorta, which typically enhances with gadolinium. Although not as widely used as CT for pre- and post-operative evaluation of aortic stent-grafts, CMR provides comparable information with regard to pre-stent anatomy and post-stent leaks. The only limitation of CMR in this setting is its inability to visualize calcium, which is important for stent graft planning. For this purpose, it can be supplemented with non-contrast computed tomography (CT).

Aortic dissection is a well-established indication for CMR, and accuracy is very high. With increasing ability to monitor acutely ill patients in the CMR suite combined with advances in imaging speed, CMR is competitive with CT for speed of diagnosis of aortic dissection. However, scanner availability and location may limit the utility of CMR in the acute setting. The intimal flap can be demonstrated and staging with regard to involvement of the ascending aorta and branch vessel involvement can be made. Gadolinium MRA is typically acquired in the aortic long-axis plane and reformatted into the axial plane for definition of the intimal flap and branch vessel involvement. Associated aortic regurgitation can be detected with cine gradient echo CMR and quantified using velocity mapping. Pericardial fluid is also easily identified and characterised. CMR is ideal for measuring aortic diameter and intimal flaps in the chronic setting, making it ideal for evaluation and follow-up of patients following surgery, and those with Marfan’s syndrome. Compared with CT, CMR avoids radiation exposure, an especially important consideration in children. When compared with transthoracic echocardiography, CMR should be considered as the first line technique in Marfan’s syndrome for imaging the aorta, because CMR is capable of visualising its entire length.

Intramural haematoma is a variant of dissection, where the false channel in the aortic wall is filled with thrombus. Dissections can include segments of both patent false lumen and intramural haematoma in the same patient, depending on the location of intimal tears, pressure in the false lumen and stage of dissection development. Flow-sensitive techniques are less accurate for the diagnosis of intramural haematoma, and more useful is spin echo imaging with T1 weighting which can detect red cell breakdown products (methaemoglobin) as a bright signal within the aortic wall in the acute and subacute stages. The use of fat saturation is helpful for distinguishing haematoma within the aortic wall from the surrounding mediastinal fat. Penetrating ulcers are a form of dissection where there is intimal erosion with either ulceration extending into the media and/or focal intramural haemorrhage. Penetrating aortic ulcer is associated with more extensive atherosclerosis, ectasia, older age but less severe hypertension than typical aortic dissection. CMR shows focal ulcerated atherosclerotic

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Indications for CMR in acquired diseases of the vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Class</td>
</tr>
<tr>
<td>1. Diagnosis and follow-up of thoracic aortic aneurysm including Marfan disease</td>
<td>I</td>
</tr>
<tr>
<td>2. Diagnosis and planning of stent treatment for abdominal aortic aneurysm</td>
<td>II</td>
</tr>
<tr>
<td>3. Aortic dissection</td>
<td></td>
</tr>
<tr>
<td>Diagnosis of acute aortic dissection</td>
<td>II</td>
</tr>
<tr>
<td>Diagnosis and follow-up of chronic aortic dissection</td>
<td>I</td>
</tr>
<tr>
<td>4. Diagnosis of aortic intramural haemorrhage</td>
<td>I</td>
</tr>
<tr>
<td>5. Diagnosis of penetrating ulcers of the aorta</td>
<td>I</td>
</tr>
<tr>
<td>6. Pulmonary artery anatomy and flow</td>
<td>I</td>
</tr>
<tr>
<td>7. Pulmonary emboli</td>
<td></td>
</tr>
<tr>
<td>Diagnosis of central pulmonary emboli</td>
<td>III</td>
</tr>
<tr>
<td>Diagnosis of peripheral pulmonary emboli</td>
<td>Inv</td>
</tr>
<tr>
<td>8. Assessment of thoracic, abdominal and pelvic veins</td>
<td>I</td>
</tr>
<tr>
<td>9. Assessment of leg veins</td>
<td>II</td>
</tr>
<tr>
<td>10. Assessment of renal arteries</td>
<td>I</td>
</tr>
<tr>
<td>11. Assessment of mesenteric arteries</td>
<td>II</td>
</tr>
<tr>
<td>12. Assessment of iliac, femoral and lower leg arteries</td>
<td>I</td>
</tr>
<tr>
<td>13. Assessment of thoracic great vessel origins</td>
<td>I</td>
</tr>
<tr>
<td>14. Assessment of cervical carotid arteries</td>
<td>I</td>
</tr>
<tr>
<td>15. Assessment of atherosclerotic plaque in carotid artery/aorta</td>
<td>III</td>
</tr>
<tr>
<td>16. Assessment of pulmonary veins</td>
<td>I</td>
</tr>
<tr>
<td>17. Endothelial function</td>
<td>Inv</td>
</tr>
</tbody>
</table>
plaque on gadolinium MRA, and/or focal intramural haematoma, best seen on T1-weighted images with fat saturation. Ulceration may also be seen as an incidental, benign finding in asymptomatic elderly patients with no or atypical symptoms and is not a cause for concern. There has been recent interest in the use of CMR for the detection of potentially embolicogenic aortic plaque. Both gradient echo or double inversion-recovery black-blood scans define aortic plaque and can monitor progression. There is good correlation between TEE and double inversion-recovery black-blood CMR for aortic plaque characterisation and thickness. A potential limitation of CMR is the identification of highly mobile plaques, which may move asynchronously with the cardiac cycle. The real-time feature of echocardiography may be advantageous for fully characterizing plaque mobility. On the other hand, CMR may be superior to echocardiography for detecting plaques in the aortic arch. CMR may be able to replace the more invasive TEE for this application if confirmed in larger studies.

Pulmonary arteries

The most common acquired disease of the pulmonary arteries is pulmonary embolism. Promising results have been obtained in several small series using gadolinium MRA. However, these scans currently require prolonged breath-holds which may be difficult to reliably achieve in this population. For this reason, as well as improved spatial resolution and access, CT remains the study of choice at many centres. MRA may be useful in patients with contraindications to X-ray contrast. Although rarer, pulmonary artery aneurysms and dissections can also be evaluated by CMR.

Extremities

The primary indication for CMR of the lower extremities is assessment of suspected atherosclerotic occlusive disease. While time-of-flight imaging is well-validated for imaging of the tibial and pedal vessels, it has been supplanted by 3D gadolinium MRA for inflow (aorta, iliac, femoral, popliteal) evaluation. Imaging of the tibial vessels using the bolus-chase approach may be compromised by venous contamination. One straightforward solution to this problem is to image the calves with an initial injection, followed by two-station bolus-chase of the pelvic and thighs. The pedal vessels can also be imaged with gadolinium MRA, although it may be difficult to integrate a dedicated pedal contrast-enhanced scan into a full lower extremity study due to contrast limitations. For limb-threatening ischaemia, gadolinium MRA has been validated for the evaluation and pre-interventional planning of peripheral occlusive disease. CMR may also be used to identify patients who may be suitable for directed endovascular interventions. There has been much less experience with imaging of the upper extremity. Gadolinium MRA works well for the great vessel origins from the aortic arch out to the axillary artery. Beyond that, time-of-flight imaging may be used with the arms positioned over the head. Gadolinium MRA has also been used for the vessels of the hand with promising results.

Renal and mesenteric arteries

Gadolinium MRA is the dominant approach for the renal and mesenteric vessels due to its reproducibility, ease of use, and efficacy. Limitations include lower spatial resolution than X-ray angiography, which remains better for quantitative stenosis measurement as well as evaluation of branch vessels and small accessory vessels. For this reason, X-ray angiography may be preferred for renal donor evaluation. On the other hand, MRA may provide more information about venous anomalies, which may be important in patients undergoing laparoscopic nephrectomy. Adjunctive imaging with either time-of-flight or phase-contrast imaging may be performed to provide additional imaging information about the renal arteries. In particular, dephasing effects seen at areas of stenosis using 2D MRA may provide qualitative information about the haemodynamic significance of lesions. CMR remains complementary to captopril renal scintigraphy and duplex Doppler evaluation of resistive index. The former provides a non-invasive arterial map, while the latter provides highly quantitative information about renal perfusion and function under conditions of stress. Several approaches to functional imaging with CMR have been described; none have achieved the level of acceptance of nuclear medicine renal functional evaluation.

Published experience with mesenteric gadolinium MRA is limited. Experience suggests similar results as for renal angiography and gadolinium MRA provides excellent images of the proximal mesenteric vessels for screening for atherosclerotic occlusive disease. Velocity mapping of the superior mesenteric artery and vein after a fatty meal challenge may be helpful for providing information about the functional significance of mesenteric occlusive disease. For more distal or detailed evaluation, X-ray angiography is currently still required.

Extracranial carotid arteries

Carotid CMR angiography using 3D time-of-flight is as accurate as X-ray angiography for measurement of internal carotid stenosis. Rapid screening of the carotid arteries for clinically significant occlusive disease can be performed using 2D time-of-flight MRA. Gadolinium MRA has been limited by the rapid jugular venous return which obscures the carotid bifurcation, but this can be improved by high temporal resolution imaging with lower spatial resolution during the arterial phase and high resolution with contrast encoding (centre of k-space) heavily weighted toward the start of the acquisition (elliptical centric). Published data has shown results with gadolinium MRA that is comparable to 3D time-of-flight MRA. Advantages of gadolinium MRA include speed,
improved coverage in the superior-inferior direction, including the arch origins, and higher sensitivity to slow flow in carotid pseudo-occlusion.

Arterial wall imaging

The arterial wall is affected with atherosclerosis long before clinical manifestations, and this provides an opportunity for early detection of CAD prior to irreversible clinical consequences. Because atherosclerosis is a systemic disease, CMR can be used to image arteries outside of the heart such as the carotid and aorta. Arterial wall CMR identifies the plaque burden and plaque constituents using a combination of T1, T2 and proton density weighted images. This has allowed the imaging of the cholesterol pool component, which is believed to significantly influence the likelihood of plaque rupture. In addition, the fibrous cap can be identified, and thin or disrupted caps have been linked with cerebrovascular events. Contrast agents have been used to further characterize plaque, show inflammation, neovasculature, and the fibrous cap. Longitudinal study of the plaque by CMR has been used to gauge the effectiveness of anti-atheroma therapy such as statin treatment, showing reduction in plaque volume, and the lipid pool. More recently, coronary wall CMR has been reported, and wall thickening and plaque constituents have been identified.

Brachial artery reactivity

Endothelial function can be examined non-invasively with stimuli which cause arterial vasodilation. Flow mediated dilation is used to examine endothelial function directly, by occluding usually the forearm using a blood pressure cuff inflated above systolic pressure for a standard time period. On release of the cuff, reactive hyperaemia causes increased endothelial shear and the release of nitric oxide (NO) which causes the brachial artery to dilate. Endothelial independent responses can also be tested by using glyceryl trinitrate, typically as a sublingual spray. Visualisation of brachial dilation with CMR can also be tested by using flow mapping, to show equivalence of LV stroke volume and aortic flow. RV volumes have likewise been validated in vivo. The accuracy of LV mass has been established directly compared with autopsy hearts from humans, and animals; and second by using flow mapping, to show equivalence of LV stroke volume and aortic flow. RV volumes have likewise been validated in vivo. In vivo accuracy of LV volume measurements is more difficult to prove, but validation work strongly suggests that CMR is accurate by 2 methods: First by showing equivalence in normal human subjects of the stroke volumes measured by the 3D contiguous slices approach of the LV and RV which must be equivalent in normals, and second by using flow mapping, to show equivalence of LV stroke volume and aortic flow. RV volumes have likewise been validated in vivo.

Assessment of ventricular function and mass

CMR is accurate, reproducible and well validated for measuring LV and RV volumes and mass; this makes it valuable for the assessment of fundamental parameters of cardiac function as well as longitudinal follow-up of patients over time. The absolute accuracy of global LV volume measurements, with a 3D approach that has no geometric assumptions, has been established ex vivo. In vivo accuracy of LV volume measurements is more difficult to prove, but validation work strongly suggests that CMR is accurate by 2 methods: First by showing equivalence in normal human subjects of the stroke volumes measured by the 3D contiguous slices approach of the LV and RV which must be equivalent in normals, and second by using flow mapping, to show equivalence of LV stroke volume and aortic flow. RV volumes have likewise been validated in vivo. The accuracy of LV mass has been established directly compared with autopsy hearts from humans, and animals. The accuracy of RV mass measurements has also been established in ex vivo animal hearts. Comparisons of CMR with echocardiography and scintigraphy are useful for guiding clinical interpretation, but are less useful for absolute validation because they show wide individual discrepancies in results compared with CMR because of their lower accuracy.

The interstudy reproducibility of CMR-derived quantitative parameters of ventricular function and mass is excellent for both the LV and RV, and has

Coronary artery disease

CMR has opened new avenues for assessing coronary artery disease (CAD) and its consequences. It provides valuable information which may not be available from other diagnostic tools such as echocardiography and nuclear cardiology which currently dominate non-invasive diagnosis in patients with CAD (see Table 3).

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Indications for CMR in coronary artery disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Class</td>
</tr>
<tr>
<td>1. Assessment of global ventricular function and mass</td>
<td>I</td>
</tr>
<tr>
<td>2. Detection of coronary artery disease</td>
<td></td>
</tr>
<tr>
<td>Regional left ventricular function at rest and during dobutamine stress</td>
<td>II</td>
</tr>
<tr>
<td>Assessment of myocardial perfusion</td>
<td>II</td>
</tr>
<tr>
<td>Coronary MRA (CAD)</td>
<td>III</td>
</tr>
<tr>
<td>Coronary MRA (anomalies)</td>
<td>I</td>
</tr>
<tr>
<td>Coronary MRA of bypass graft patency</td>
<td>II</td>
</tr>
<tr>
<td>MR flow measurements in the coronary arteries</td>
<td>Inv</td>
</tr>
<tr>
<td>Arterial wall imaging</td>
<td>Inv</td>
</tr>
<tr>
<td>Acute coronary syndromes</td>
<td>Inv</td>
</tr>
</tbody>
</table>
been shown to be considerably superior to 2D and m-mode echocardiography.55,149 This allows the reduction of sample sizes in drug studies.162,163 Phase 2 trials and sub-studies in phase 3 trials are being conducted using CMR as primary endpoints.164,165

Regional contractile function is also well-assessed by CMR with visual inspection of cines or quantification of wall motion and thickening for both the RV,166,167 and LV.168–171 However, the CMR tagging technique permits the determination of the strain of the myocardium as a measure of contractility.172 By monitoring the progressive distortion of the tags during the course of the cardiac cycle, regional ventricular strain myocardial rotational deformation, ventricular non-uniformity, and differences in endocardial and epicardial wall motion can be calculated.173 This can be fully resolved in 3D to cover the entire heart.174 CMR tagging has been validated against invasive sonomicrometer studies,175 and has been used to discriminate infarcted from remote myocardium.176

Detection of coronary artery disease

There are several approaches to detecting CAD using CMR. These include the visualization of the effects of induced ischaemia (wall motion, perfusion) and direct visualization of coronary arteries (coronary angiography and flow). Early detection of atherosclerosis and endothelial dysfunction is also possible (arterial wall imaging, brachial artery reactivity).

Stress wall motion abnormalities

Physical exercise within the magnet leads to degradation of image quality from motion artefacts, and therefore pharmacologic stress is more commonly used. Dobutamine is ideal for this,177–180 with superior results compared with dipyridamole.181–185 Dobutamine stress CMR is well established as a technique for identifying ischaemia-induced wall motion abnormalities in CAD, with guidelines for clinical practice.186 Breath-hold gradient echo or SSFP cines are used to examine regional wall function throughout the LV before and during stress. Diagnostic results are very good and direct comparison data with dobutamine stress echocardiography have shown superiority of CMR,187 due to higher quality imaging.188 Dobutamine stress CMR has been shown to be very effective in the diagnosis of CAD in patients who are unsuitable for dobutamine echocardiography.189 Quantification of LV wall motion and thickening using CMR using the centreline method may improve the accuracy for detection of patients with single vessel CAD.190 There is a low event rate when dobutamine CMR is normal,189,191,192 and a higher event rate in the presence of ischaemia.191 CMR has also been used for pre-operative risk assessment.193

Other CMR techniques have been used to assess CAD during dobutamine. Tagging methods194,195 have shown increased sensitivity for diagnosis of CAD.192 Objective analysis using tagging would be expected to reduce observer interpretation variability, which is well recorded for dobutamine stress echocardiography,196 and application of this CMR technique in a large clinical trial is awaited. In the MR environment, the ECG is uninterpretable with regards to STT wave change. Real-time CMR may be used to monitor wall motion and may eliminate the need for breath-holding.197 Diastolic function has been shown to be abnormal using dobutamine CMR in CAD,198,199 and parameters of global ventricular function such as flow acceleration are affected by dobutamine-induced ischaemia.200 Further work is required to determine the clinical role of these techniques.

Myocardial perfusion

Myocardial perfusion CMR now achieves comprehensive ventricular coverage using multi-slice imaging in contiguous short axis, or mixed short and long axis planes. An intravenous bolus of gadolinium contrast agent (up to 0.1 mmol/kg) is given usually in the antecubital fossa with a power injector to allow a fast and consistent injection rate (typically 5–7 mL/s). Ideally, imaging is performed on every ventricular plane with each cardiac cycle. Visual interpretation to identify dark areas of low perfusion may be performed, or the myocardial signal may be measured during the first pass for computer analysis. Quantification can be performed by measuring the upslope of myocardial signal increase and the plotting of colour parametric perfusion maps.201,202 More complex analysis includes respiratory motion correction,203 and deconvolution analysis allowing for the input function from the LV blood pool signal curve,204 in order to generate regional values for quantitative perfusion index and myocardial perfusion reserve. These techniques have been extensively reviewed,205,206 and validated in animal models.207–209 In humans in vivo, validation against perfusion reserve and absolute blood flow by PET has been performed.202

For clinical application, CMR perfusion is still in development, and two clinical scenarios are being tested. First, the simple approach of assessing stress myocardial perfusion only during vasodilatation, and using late gadolinium enhancement to define areas of non-viability. Second, is the use of both stress and rest myocardial perfusion scans, which is more akin to conventional nuclear cardiology procedures, and has the benefit of allowing the generation of myocardial perfusion reserve measurements.210,211 In clinical studies for the detection of CAD, the results of myocardial perfusion CMR are very good in comparison with X-ray coronary angiography,201,202,211 PET,202 and SPECT.201 CMR has shown improvement in myocardial perfusion reserve after coronary angioplasty,213 reduced perfusion in hypertrophic cardiomyopathy,214 and impaired subendocardial perfusion in cardiac syndrome-X.215 A technique called T2* blood oxygen level dependent (BOLD) has also recently been described, which allows measurement of myocardial perfusion without the use of a contrast agent.216–219 The clinical role of the BOLD technique is promising,220 but not yet fully defined.

Coronary angiography and flow

MRA is used routinely for evaluation of the arteries and veins throughout the body, but coronary MRA is techni-
Clinical indications for cardiovascular magnetic resonance

Clincially more difficult due to their small size, tortuosity, complex 3D anatomy, and near incessant cardiac and respiratory motion. Using 3D acquisitions and modern optimized sequences, both breath-hold, and navigator techniques, have been used. A multi-centre trial has shown 81% negative predictive value for the exclusion of multi-vessel proximal CAD. However, the current spatial resolution and residual motion during the acquisition period, restricts the assignment of diameter stenosis severity to broad categories, and distal vessel assessment of run-off for surgical planning is still problematic. The application of coronary MRA for the assessment of the course of anomalous coronary arteries is well established however, and is usually undertaken after X-ray angiography to ensure that the proximal portion does not have a malignant course between the aorta and pulmonary artery. A different approach to detecting CAD by CMR is the noninvasive measurement of coronary flow velocities. Determination of coronary flow by CMR at rest and after adenosine has been reported in animals, and in humans. The use of coronary flow reserve in humans has been reported for identifying stenosis of the left anterior descending artery, and instant restenosis.

CMR sequences can also be used to image coronary vein grafts. Both spin echo, and gradient echo imaging, yield accuracies in predicting graft patency of around 90%. This may prove useful in early post-operative chest pain syndromes in order to exclude graft occlusion. Bypass graft flow has proved useful in identifying diseased vein grafts through reduced baseline flow and flow reserve, and may further define focal stenoses.

Assessment of chronic coronary syndromes

Myocardial infarction (MI) can be detected with high accuracy and sensitivity using late gadolinium-enhanced CMR. Gadolinium (0.1—0.2 mmol/kg) is given intravenously and after 10—20 min, CMR is commenced using an inversion recovery sequence, where the inversion time is chosen to null myocardial signal. Because normal myocardium is uniformly tightly packed with muscle, and gadolinium is an extracellular contrast agent, there is uniformly low signal in the normal heart. In areas of MI, the extracellular compartment is expanded, and in addition, gadolinium wash out from these areas is slow. This leads to a higher gadolinium concentration on the late enhancement scan, which shows as bright signal, and has lead to the aphorism “bright is dead”. Because CMR has high resolution, it is possible to determine the transmural distribution resolution of MI in vivo. The technique has been extensively validated in animal models, and has now replaced other CMR techniques for detecting MI. In humans, late gadolinium enhanced CMR has been shown to accurately detect both Q-wave and non-Q wave MI. Because the technique is so sensitive, CMR has been shown to identify sub-endocardial MI when wall motion and perfusion by SPECT are normal.

In the assessment of myocardial viability for the clinical scenario of consideration of bypass surgery for improvement of LV function, CMR has been shown to be very useful. As CMR accurately measures wall thickness, which is reduced in chronic transmural MI, this has been used to exclude the presence of viable myocardium in chronic infarcts with good correlation to positron emission tomography (PET) findings using fluorodeoxyglucose (FDG). In dysfunctional areas where wall thickness is preserved, viability can be established by demonstrating improved thickening during low-dose dobutamine infusion, and again correlation with FDG-PET is good. Late gadolinium-enhanced CMR has also been tested for prediction of viability, and when the transmural extent of infarction is <50%, the likelihood for functional recovery in acute MI, or with bypass surgery is good. Reproducibility is good, direct comparisons with PET are excellent, and CMR has been shown to be superior to thallium SPECT.

Evaluation of acute coronary syndromes

CMR has been used in the emergency room in the assessment of chest pain. CMR showed a sensitivity and specificity of 84% and 85% for identifying patients with CAD, and multi-variate analysis including standard clinical tests (ECG, troponin, TIMI risk score) showed that CMR was the strongest predictor of CAD and added diagnostic value over clinical parameters, including identification of enzyme-negative unstable angina. This promising data needs to be confirmed in other centres.

CMR also identifies microvascular obstruction in acute MI. This is demonstrated early (1—2 min) after intravenous injection of gadolinium. At this time, which is well before late gadolinium-enhancement CMR would be performed, inversion recovery CMR shows areas within the MI which have severely compromised perfusion as black, and this indicates areas with microvascular collapse. Microvascular obstruction detected by CMR has been linked to ventricular remodelling, and adverse cardiovascular events. Finally, the transmural extent of late gadolinium-enhancement CMR predicts recovery of function following acute MI.

CMR is effective in demonstrating the complications of acute MI including ventricular aneurysm, pseudoaneurysms, ventricular septum perforation, and mitral regurgitation. As echocardiography may yield false positive and false negative results when looking for LV thrombi in post-infarction patients, CMR is useful.

Cardiomyopathies and cardiac transplantation

The cardiomyopathies include a variety of diseases where the primary pathology directly involves the myocardium excluding CAD. CMR is proving increasingly
valuable in the identification and management in these conditions (see Table 4).

**Hypertrophic cardiomyopathy**

Clinically, hypertrophic cardiomyopathy (HCM) requires an accurate diagnosis, determination of the distribution of hypertrophy and its functional consequences, and assessment of the likelihood of sudden death and progression to heart failure. Two-dimensional and Doppler echocardiography are the most commonly used non-invasive methods to study HCM. CMR myocardial tagging identifies abnormal patterns of strain, shear and torsion in HCM, demonstrating significant dysfunction in hypertrophic areas. Late enhancement gadolinium CMR has also been used in HCM to demonstrate areas of fibrosis and the extent of this abnormal uptake is linked to the risk of sudden death and heart failure. CMR has also been used to identify the functional and anatomical consequences of septal resection, and percutaneous ablation. Serial CMR therefore permits complete assessment of the morphologic and functional consequences of the disease, is ideal for screening of relatives because of its phenotypic accuracy, and its ability to identify abnormal myocardial substrate linked to adverse events. Therefore, especially in patients in whom echocardiography is technically unsatisfactory, CMR should be considered the technique of choice for diagnosing and following patients with all variants of HCM. Finally, it is now known that about 4% of patients who present clinically with HCM actually have Fabry’s disease. Gadolinium enhanced CMR shows unusual lateral wall enhancement in these patients, and further work is required to evaluate this finding.

**Left ventricular hypertrophy**

LV hypertrophy is an important independent risk factor for cardiac events. CMR is the best technique for assessing LV mass and following its progression over time (both for research trials and for clinical patients), because of excellent interstudy reproducibility. This condition has become more recognised, and appears to have autosomal dominant inheritance. There is a failure of normal embryonic development of the myocardium from loosely arranged muscle fibres to the mature compacted form of myocardium. This has been linked with microvascular dysfunction and ventricular arrhythmias. Variant forms seem to include left ventricular trabeculation which appears as a fine network or is more bizarre, CMR appears ideal for identification of this condition, but there are no large comparison studies with echocardiography.

**Dilated cardiomyopathy**

The morphological and functional abnormalities of dilated cardiomyopathy (DCM) are clearly demonstrated and quantified by CMR. These findings may not distinguish DCM from other forms of LV dysfunction, such as that resulting from CAD. An advantage of CMR over echocardiography is the use of late gadolinium enhancement CMR, which shows no uptake in a majority of DCM patients. This confirms the diagnosis and precludes the need for invasive coronary angiography. In some DCM patients, late gadolinium enhancement is seen, but only in the mid-myocardium in a non-coronary pattern which is clearly distinguishable from CAD, and is recognized by pathologists as mid-wall fibrosis seen at post-mortem. Another advantage of CMR is the superior depiction of dilation of the RV which is typical of DCM. The quantitative effects of therapy can also be assessed by CMR.

**Arrhythmogenic right ventricular cardiomyopathy**

CMR is an ideal technique to depict the structural and functional abnormalities of the RV and a substantial clinical role for CMR in the investigation of arrhythmogenic right ventricular cardiomyopathy (ARVC) has developed. The diagnostic criteria of ARVC, which CMR can show in the RV include regional wall motion abnormalities, increased RV volumes with quantification, morphological abnormalities (aneurysms, trabecular disarray) and increased myocardial signal suggesting fatty infiltration. Early work suggests that abnormal CMR find-
ings predict an adverse outcome in ARVC. Experience in interpretation of CMR is required however, because of the normal variants of the RV which are in general greater than for the LV. Therefore isolated findings must be interpreted with caution. Focal wall motion abnormalities, especially focal dyskinesia, is generally felt to be a more reliable indicator of ARVC than intramyocardial fat. Overall, in centres with good experience however, CMR is a first line technique for investigating ARVC and following any progression in RV volumes, structure and function over time.

**Siderotic cardiomyopathy**

An often overlooked cause of heart failure which is important worldwide, is iron overload cardiomyopathy arising in patients with haemochromatosis or the inherited severe anaemias which require regular blood transfusions from birth. The most important of these conditions is beta-thalassemia major, with 60 000 affected children born annually. Over 70% of these patients die from heart failure. Repeated assessment of myocardial iron using biopsy is difficult because of safety issues, sampling error and patchy iron distribution. Recently, measurement of T2* using CMR has been shown to reflect tissue iron, and there is a clear relation between reduced myocardial T2* (<20 ms) indicating iron overload, and LV dysfunction. Myocardial T2* increases in concert with LV function recovery in thalassemia patients with heart failure. CMR has been used to evaluate different chelation regimes specifically for their action on the myocardium. The CMR sequence can be completed quickly in a single breath-hold, and has good reproducibility.

**Restrictive cardiomyopathy**

CMR may be useful to depict the anatomic and functional abnormalities associated with infiltrative/restrictive cardiomyopathy. Amyloid heart disease can be recognised by its typical alterations of diastolic function and morphology, including thickening of the interatrial septum. Another contribution of CMR is the of visualisation of the pericardial thickness with spin echo CMR which aids in the differentiation from constrictive. Computed tomography may have similar accuracy in making this distinction.

**Cardiac sarcoidosis**

Although cardiac involvement in sarcoidosis is relatively uncommon, sudden death may be its initial clinical presentation and early detection of such involvement is thus important. However, clinical information and standard imaging techniques suffer from low diagnostic accuracy. There are reports of the value of CMR in this condition. Gadolinium-enhanced CMR demonstrates increased signal in hearts affected by sarcoidosis, which reduces with steroid treatment and is therefore a potential therapeutic marker.

**Myocarditis**

The clinical diagnosis of myocarditis is difficult as symptoms are variable and often non-specific. Myocardial biopsy carries some risk and is limited by the patchy involvement of the muscle in the inflammatory process. CMR shows focal increases of myocardial signal on T2-weighted and early gadolinium enhancement CMR (1–2 min) in acute myocarditis, and also with late enhancement.

**Heart transplantation**

The two most common clinical problems in patients following heart transplantation are detection of episodes of acute rejection, and identification of accelerated coronary artery disease commonly considered as chronic rejection. Acute rejection can be identified as an increase in myocardial mass, areas of high myocardial signal intensity, and an increase in T2 values. These findings correlate with myocardial oedema or infiltration by mononuclear cells. However, these changes, as well as reductions in LV wall thickening, are not reliable indicators of acute rejection, particularly not in the early stages. CMR may help detect CAD associated with cardiac transplantation complications such as pericardial disease or intracavitary masses, and the beneficial effects of medical treatment, on the remodelling process associated with long term use of cyclosporin.

**Pericardial disease**

Both CMR and CT are well suited to define anatomic abnormalities of the pericardium including pericardial thickening and effusions. CMR has the advantage of being able to depict and quantify the functional abnormalities which may be associated with pericardial disease. The large field of view of CT and CMR is helpful in providing a better overview of the extent of pericardial disease, and to define the relationship with surrounding anatomic structures. For suspected pericardial thickening, CMR and CT are primary imaging modalities, with CT having an advantage for identification of pericardial calcium.

**Pericardial effusions**

Gradient echo and SSFP cine CMR generally show pericardial effusions with high signal intensity. CMR may be of diagnostic value in patients with loculated or complex configurations of pericardial effusions.

**Constrictive pericarditis**

The characteristic anatomic and functional changes associated with constrictive pericardial disease (elongated and narrow RV, abnormal motion of the sigmoid shaped interventricular septum, enlargement of the right atrium and inferior caval vein, stagnant blood in the atria, and
pericardial thickening) are clearly identified with spin echo CMR.329,330

Pericardial thickening is the hallmark of pericardial constriction although cases of constriction without pericardial thickening detectable by imaging techniques have been described.329 Both spin echo CMR and CT are superior to echocardiography in measuring pericardial thickness but CMR has the additional advantage of permitting assessment of haemodynamic impairment. However, in patients with severe heart failure and in those with poorly controlled atrial fibrillation, CT may be preferable to CMR because imaging time is shorter and ECG gating is not required. The reliability of CMR in making a diagnosis of pericardial constriction is indicated by its high positive predictive accuracy.329

Velocity mapping of flow may be helpful to assess functional sequelae of pericardial disease.331 Flow mapping may be performed at the level of cardiac inflow through the superior or inferior vena cava, where a normal biphasic flow pattern may be demonstrated. In patients with constrictive physiology and abnormal cardiac filling, the second peak of caval flow may be attenuated.

Congenital abnormalities of the pericardium

Pericardial cysts can be identified and distinguished from other tumours based on their characteristic signal intensity on spin echo images, which is low on T1-weighted but high on T2-weighted images. Signal is usually high on gradient echo cines. However, differential diagnosis from a necrotic or cystic mediastinal tumour, especially if it is situated in the typical location for a pericardial cyst, the right costophrenic angle, may be difficult. Absence of the pericardium is indicated by a leftward shift of the long axis of the heart visible using CMR.332 The protrusion of a portion of the heart, which is usually associated with partial absence of the left-sided pericardium is easily observed on spin echo images. However, due to the absence of epicardial and epipericardial fat over the left ventricle, the pericardial defect itself may not be seen on spin echo images.333

Cardiac tumours

Transthoracic echocardiography is the usual technique which detects intracardiac tumours. However, in many cases the characterization is incomplete, and CMR is particularly helpful in determining the relationship to normal intracardiac structures and tumour extension to adjacent vascular and mediastinal structures,334 infiltration into the pericardium,335 and surgical planning.336 In addition to this, there are a number of CMR features which can assist in tumour characterization.337,338 The signal intensity of a lesion is dependent on the interaction of the tissue composition and the CMR parameters employed for imaging. The differential diagnosis of a high signal intensity lesion on T1-weighted images includes fatty tumours (lipoma, liposarcoma), recent haemorrhage (due to methaemoglobin breakdown products), some cystic lesions (due to the high protein content of the contents of the cyst), and melanoma (due to the effects of melanin). A lesion with low signal intensity on T1-weighted images may represent a cyst filled with low protein fluid, a signal void in a vascular malformation, a calcified lesion or the presence of air. Cysts typically have high signal intensity on T2-weighted independent of the protein concentration of the fluid. Fat saturation can be used to diagnose fatty content definitively. Further differentiation of the tumour can be made with gadolinium. During the first pass, vascular tumours (haemangioma, angiosarcoma) show early enhancement and small vessels may be easily identifiable. In the early phase, after injection at 1–2 min, necrotic areas in malignant tumours show as dark areas surrounded by enhancement elsewhere. In the later phase, malignant tumours typically show contrast enhancement indicating tissue vascularity. Such enhancement is usually absent in cystic lesions, and most benign tumours (haemangiomas and myxomas being exceptions). Thrombus in the ventricles is well shown by modern CMR sequences, including SSFP cine, and late gadolinium enhancement,270 and for this application may be more sensitive than echocardiography.

Valvular heart disease

The low cost, flexibility and ease of handling make transthoracic echocardiography the primary clinical tool for evaluation of valvular heart disease. Moreover, TEE is superior to CMR in assessment of valve morphology and detection of small and rapidly moving vegetations attached to the valves in endocarditis. However, CMR may play a complementary role when transthoracic acoustic windows are poor and a TEE approach is undesirable, or when results of echocardiography and catheterization are conflicting. Furthermore, CMR is a valuable tool for individual follow-up of the severity of regurgitant lesions and for quantification of the effects of valvular lesions on ventricular volumes, function and myocardial mass (see Table 5).

Technical aspects

As normal heart valves are thin and rapidly moving, visualization on conventional spin-echo images may be difficult but breath-hold spin-echo techniques allow complete visualization of normal aortic valve leaflets in 85% of patients.339 Abnormal valves are more easily seen because they are thicker and may be less mobile. Calcifications give rise to loss of signal and may lead to underestimation of valve pathology on spin-echo images. Generally, gradient echo cines are more informative as myocardial and valvular function are dynamically displayed. A phenomenon characteristic of older gradient-echo cine CMR is referred to as intravoxel dephasing.
which leads to signal loss demonstrating turbulence found in heart valve lesions. This signal-loss can be seen in the proximity of rapidly moving valves or at sites of stenoses where flow is accelerated and turbulent. Jets of signal-loss indicate valvular stenosis or incompetence. Whilst the length and area of the signal-loss jet help to indicate the severity of the valvular defect, they are only semi-quantitative, because the extent of the jet depends on the combination of haemodynamic variables such as size and shape of the valve orifice, the pressure gradient, and technical parameters of the pulse sequence. Modern CMR systems with high gradient performance typically acquire cines using the SSFP technique, which is less dependent on the inflow of magnetically non-saturated blood within the imaging slice. This makes the blood appear brighter, and it is less sensitive to intravoxel dephasing thereby reducing the jet of signal loss.

Velocity mapping CMR is a well validated approach to quantify blood flow velocity in large vessels, and is useful to quantify the severity of regurgitant and stenotic valve lesions. The direction of velocity is generally obtained through-plane with the imaging plane perpendicular to the direction of flow. Integration of velocities over the cross-section of a vessel yields flow rate (mL/s) when multiplied by the vessel cross-sectional area. By integration over the entire cardiac cycle, the stroke volume is obtained. New technical developments include adaptation of the imaging slice to motion of the valve annulus with simultaneous correction of the velocity measurements to through-plane motion of the heart, and realtime colour flow CMR.

### Regurgitation

Valvular regurgitation is identified by means of the jet of signal loss on cine gradient echo CMR, but the size of the jet is highly sequence-dependent. A quantitative assessment of single valve lesions can be obtained by calculating the regurgitant volume from the difference of RV and LV stroke volume. If single valves on both sides of the heart are regurgitant, the method can be extended to determine regurgitant volume from the subtraction of the ventricular stroke volume from the great vessel flow on the same side. Regurgitant fraction is calculated as the regurgitant volume divided by the ventricular stroke volume.

Aortic regurgitation may be associated with a semicircular shaped signal void proximal to the leaking orifice during diastole. Using velocity mapping CMR, the aortic regurgitant volume and fraction can be obtained directly by measuring the retrograde volume flow in diastole in the ascending aorta. This simple and direct approach is more quantitative than Doppler, and has been used to identify patients responsive to angiotensin-converting enzyme inhibitor therapy, and hydralazine. It has high interstudy reproducibility, which is valuable for repeated estimations. The flow acquisition should be placed between the aortic valve and the coronary ostia to avoid inaccuracies from aortic compliance and coronary flow.

Mitral regurgitation may be central or eccentric, and can be quantified by comparing total LV stroke volume derived from short axis multi-slice volumetry with the net forward stroke volume obtained with velocity mapping CMR in the ascending aorta. This method compares favourably with catheterization and Doppler echocardiography. More direct methods for measuring systolic regurgitant flow and ventricular inflow at the mitral annulus level are complicated by through-plane motion of the annulus and by eccentricity of the regurgitant jet. Methods to correct for inaccuracies have been developed but are currently not routinely available.

### Stenosis

Bicuspid or fused aortic valves can be identified with accurate positioning of the imaging plane in early systole perpendicular to the doming valve leaflets. Direct planimetry of the orifice area is also feasible.Calcification of the leaflet tips may be difficult to differentiate from signal loss due to turbulence and may thus lead to overestimation of the valve opening area, however, calcifications are usually located within the cusps and interference with measurements of valve area is uncommon. Non-uniform and accelerated flow distal to an abnormal valve causes signal loss in cine gradient echo cine CMR and may indicate valve stenosis. The extent of the jet cannot be used as an accurate measure of stenosis severity because of its dependency on settings of CMR parameters. For example, a short TE reduces the magnitude of the signal void. Using velocity mapping CMR, the peak velocity within the core of the jet can be measured in alignment with the jet direction or perpendicular to it, and the modified Bernoulli equation used to estimate the pressure gradient. Short TE sequences are required to avoid loss of velocity information in areas of turbulent flow. Close agreement has been demonstrated between CMR, catheterisation and Doppler echocardiography in patients with mitral and aortic valve stenosis.

As valve area measurements by cardiac catheterization may be complicated by occult strokes, CMR could be used to quantify the valve area in aortic stenosis when echocardiography is not
possible or non-concordant data with invasive techniques have been obtained.

Prosthetic valves

CMR is safe in patients with prosthetic heart valves at 1.5 Tesla, as the heart valve prostheses have no substantial interactions with the magnetic field and heating is negligible. However, they do produce focal artefacts and signal loss due to distortion of the magnetic field by the metal contained within the prostheses. The artefacts are least pronounced on spin-echo images and more pronounced with gradient-echo cines. As a consequence, smaller jets of signal loss due to paravalvular leakage may be obscured by the artefact. Heart motion-adapted velocity mapping has allowed the measurement of velocity profiles close to aortic valve prostheses.

Cardiovascular magnetic resonance spectroscopy

CMR spectroscopy for clinical purposes is presently limited to the study of P-31 containing myocardial phosphates present in important biochemical compounds involved in energy metabolism. Compounds such as adenosine triphosphate (ATP), phosphocreatinine (PCr), inorganic phosphate (Pi) and monophosphate esters (MPE) can be studied at rest and during stress. Although other important elements can be studied by CMR spectroscopy, none are currently used clinically. Nevertheless, potentially clinically relevant results have been reported with in vivo human studies of hydrogen (H-1), sodium (Na-23), and potassium (K-39). The main reason for their limited clinical application is the low MR sensitivity of other nuclei and their low concentration, which results in a very low signal. At present, CMR spectroscopy can only interrogate anterior portions of the heart, but higher field strength magnets and new coils should improve the coverage.

A primary clinical goal of CMR spectroscopy is to determine the PCr/ATP ratio, which reflects the energetic state of the myocardium. Important conceptual studies suggest that the unique ability to interrogate the high energy pathway has significant diagnostic and prognostic potential. In mild heart failure, the PCr/ATP ratio is in the normal range, but falls with advancing severity. Reduced PCr/ATP ratios improve with treatment of heart failure, and the level of PCr/ATP is an independent predictor of cardiovascular events which may be more predictive than ejection fraction. In patients with valvular disease, PCr/ATP ratios are reduced only when patients develop heart failure but not in early stages. Whether PCr/ATP ratios can be used clinically to guide the timing for valve replacement is currently unknown. In CAD, myocardial ischemia induced during handgrip exercise can be detected by transient reduction in the PCr/ATP ratio. This response is abolished by revascularization. This ischaemic response is not seen in non-viable regions. Viable myocardium has been shown to have normal absolute levels of ATP, but levels are low in non-viable myocardium. Stunned myocardium has been shown to have normal PCr/ATP ratios. Taken together, these results suggest that CMR spectroscopy can provide metabolic evidence for myocardial viability. In early cardiac allograft rejection, decreased PCr/ATP ratios are seen, although this must be distinguished from transient reductions early after transplantation that might occur on the basis of transient allograft ischemia. In LV hypertrophy, the PCr/ATP ratio is generally normal, but reductions are seen in hypertrophic cardiomyopathy. The reasons for this are not currently understood. Finally, a decrease in PCr/ATP ratio has been found in 20% of women with chest pain in the absence of significant epicardial coronary artery stenosis, a result which suggests the presence of microvascular disease and resultant ischaemia.

Costs and benefits of CMR

This section focuses on the USA and UK where cost data and technology assessments of CMR have been undertaken; the principles apply however to most European Union (EU) countries and elsewhere. There are a number of medical society and governmental position papers on the economic value of CMR and other imaging techniques, and these are a useful further reference source for independent assessments of cost-benefit. A large amount of data reveals that there is a large economic burden placed upon society for the use of imaging tests for cardiovascular disease. For example, high rates of resource consumption are noted in the US (~$40 million non-invasive cardiac tests are performed annually for public and private health care payers; Medicare reimbursement of $372–$740 million; and high growth rates >20% using Medicare databases for some cardiac imaging modalities). The same applies in most countries of the EU, but in some there is underutilization of procedures. In this latter case, the opportunity exists that societal investment in more accurate and diverse technology may supplant the use of inexpensive and less accurate diagnostic testing modalities. This might be feasible in the more urban or centralized health care environments.

Current efforts to contain health care costs in the US and Europe have included developing evidence-based guidelines where a threshold body of clinical and economic evidence is desired to support and guide reimbursement for a given clinical procedure indication. Despite the concern over excessive and rising costs of care, the current armamentarium for cardiac imaging has suffered from technical artefacts, limited resolution, and other challenges that often provide a unidimensional risk evaluation upon which patient management is based. Thus, the promise to society for CMR is to develop strategies that provide a full range of risk markers which would allow health care systems to benefit from improved diagnostic accuracy, risk assessment and thera-
peutic decision making. The resultant economic effects of these improvements may result in decreases in overall test use, early diagnosis, improved patient outcome, decreased hospitalizations and length of stay, and reduced invasive procedure use. As many countries currently track cardiovascular mortality rates, the impact of early diagnosis on long-term survival may provide a link to shifting health care resources and the decision to utilize differential technology in order to exhibit a more beneficial impact on population-based risk reduction efforts.

Cost implications of functional CMR

CMR permits accurate and precise measurements of cardiac chamber sizes and volumes, rendering it ideal to detect abnormalities in complex diseases. A hierarchical testing approach in which lower cost tests are applied to a greater percentage of patients and higher cost tests are limited to high-risk patients where a greater incremental value is determined, is based upon high-risk cost effectiveness model in which economic value is greater in higher risk populations who receive a greater proportional benefit to testing and treatment (in the form of disproportionately greater risk reduction when compared to lower risk cohorts). By applying this principle of high-risk cost models, costs can be differentially and selectively allocated to sicker patients and thereby result in more cost efficient care shifting higher risk patients from ultrasound or nuclear-based techniques to CMR. Additionally, the upfront cost differences are minimized by the greater outcome benefit to that patient cohort, rendering the test more cost effective.

Cost implications of CMR perfusion and viability testing

CMR has the potential to provide myocardial perfusion measures. Evidence in small patient samples reveals a sensitivity and specificity of 87% and 85%, respectively, versus catheterization as the gold standard, and improved detection of infarction versus SPECT. A considerable amount of diagnostic and prognostic data are available with SPECT however and despite a substantial radiation burden of SPECT, it appears that perfusion CMR may take time to become competitive due to the current favourable reimbursement for perfusion SPECT, with function as an add-on. The detection of subendocardial ischaemia by CMR techniques could prove to be clinically and cost effective for large segments of the SPECT population (for example women evaluated for chest pain symptoms).

Despite this initial caution on the use of perfusion, viability testing with CMR may become the gold standard for the assessment of patients with LV dysfunction presenting for evaluation and consideration of coronary revascularization. Using a model of high risk cost-effectiveness, evidence of CMR viability would result in improved patient outcome with coronary revascularization and reduced cost (due to reduced hospitalisations for heart failure, acute myocardial infarction, etc.).

The incremental cost effectiveness ratio of viability testing with CMR when compared with echocardiography, SPECT, or PET techniques could result in a dominant economic strategy of improved life years saved and cost savings.

Cost implications of coronary CMR

Currently, 1.2 million diagnostic coronary X-ray angiograms are performed annually in the USA which carries a small risk due to the invasive procedure, the contrast media, and the radiation exposure. Although under development, coronary MRA provides an opportunity to reduce these risks. If coronary MRA could be utilized to screen lower risk patients currently referred for catheterization, substantial cost savings may be achieved amongst the patients with normal catheterization (current rate in USA approximately 35%). In one report, the total cost savings, when compared to diagnostic coronary angiography, was expected to exceed $1000 per patient (or >60% cost reduction).

In the area of carotid and peripheral MRA, there are existing cost effectiveness analysis that may be used to guide the utilization of these techniques. In a recent review by the UK’s National Institute of Clinical Excellence (NICE), the high sensitivity (93%) and specificity (94%) in the detection of carotid disease, resulting in cost-effectiveness ratios of £19 419 (approximately €27 000) per quality adjusted life years saved. Thus, in the evaluation of carotid disease, MRA was the cost-effective test of choice. A cost-effectiveness analysis was also performed by NICE in the evaluation of peripheral arterial disease comparing MRA (94% sensitivity and 93% specificity) with X-ray angiography. There was little difference in 1 year outcomes, a small complication risk with the invasive angiography and reduced costs with MRA. Thus, MRA was considered the favourable choice, except for the highest risk patients who should be referred to X-ray angiography.

Cost implications for the pharmaceutical industry

It costs an estimated $500 million to bring a new drug to the marketplace. Although the majority of drug development costs are in preclinical research, the average cost of FDA-sponsored Phase I to IIb clinical trials ranges from $14 to $54 million. There is increasing interest on the part of pharmaceutical manufacturers to reduce the frequency with which large morbidity and mortality outcome trials are utilized by re-focusing resources early on in drug development to areas of distinct clinical promise. An alternative to the use of large outcome trials is to use an imaging or laboratory marker as a surrogate outcome. A surrogate outcome is, by definition, a process of care measure that may be used to reflect a worsening long-term outcome (e.g., worsening ejection fraction). Due to the enhanced reproducibility of CMR measurements, it appears ideally suited for use as a surrogate outcome. Prior research supports the view that CMR
can reduce the necessary and sufficient sample sizes by as much as 10-fold and decrease overall cost by as much as 80%. Using simple cost calculations, approximately 5–11% of drug development costs may be saved thus providing substantial reductions in costs to society.

Comparative test costs

The current estimated costs of cardiac imaging modalities are shown in Table 6. As a number of CMR techniques are currently under development, these cost estimates should be viewed with caution. Despite this, the estimated unit procedural cost (not charge) of CMR ranges from €194 to €1063 based upon multiple sources. Current estimates of CMR costs are expected to decline over the next decade as training costs, initial protocol development, and equipment costs contribute to higher initial development costs for this modality. An example of lower achieved costs can be seen in the area of more mature CMR techniques, such as can be seen with peripheral MRA techniques. As is noted with vascular MRA costs, in the UK the unit cost for some MR procedures has been estimated at £110 and £247 for evaluation of carotid arteries and peripheral vasculature. Upon reviewing the initial cost estimates, it appears that CMR is quite cost competitive when compared to other modalities. One would anticipate with continued use and protocol refinement, enhanced efficiency and cost reductions for CMR will ensue.

Test use is guided by both economic forces, such as reimbursement, and information content. For CMR, the multitudes of test parameters that can be acquired render this test unlike other non-invasive imaging modalities. Its ability to acquire diverse risk markers may, in some cases, raise the overall procedural cost but its upfront cost may be minimized by substantial downstream cost savings. Economic value may be achieved by developing a single, non-invasive test that assesses all aspects of the heart, and CMR has the potential to provide this comprehensive examination in one sitting at considerably less risk and cost to the patient. With rapid imaging techniques, it should be possible to complete a comprehensive study in as little as one hour, at an estimated median cost of €435. The effect of this initial test cost may be offset by a reduction in downstream utilization of other redundant imaging tests. Using a rudimentary cost analysis, adding the ability of CMR to perform multiple test functions may therefore provide cost savings to the health care system.

References

3. Higgins CB, de Roos A. Cardiovascular MRA and MRI. Lippincott Williams & Wilkins; 2003.

<table>
<thead>
<tr>
<th>Table 6</th>
<th>Estimated average costs of CMR and other common cardiac imaging procedures when compared to 2D echocardiography</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echocardiography</td>
<td>Average Cost</td>
</tr>
<tr>
<td>Computed Tomography</td>
<td>3.13</td>
</tr>
<tr>
<td>SPECT</td>
<td>3.27</td>
</tr>
<tr>
<td>CMR</td>
<td>5.51</td>
</tr>
<tr>
<td>PET</td>
<td>14.03</td>
</tr>
<tr>
<td>Right and Left Heart Catheterization</td>
<td>19.96</td>
</tr>
</tbody>
</table>

* Echocardiography is the cost comparator where costs of other modalities are a ratio of x-fold higher costs. Note: Costs are unit operating costs (not charges) derived from multiple sources. CMR cost does not include the cost of intravenous contrast agents or stress protocols. Conversion of US Costs to Euros based upon CPT codes: 75552, 75553, 75554, 75555 (based upon average for Atlanta, Georgia, US, August 19, 2003).
Clinical indications for cardiovascular magnetic resonance


Clinical indications for cardiovascular magnetic resonance


Clinical indications for cardiovascular magnetic resonance
1961


287. Myerson SG, Montgomery HE, Whittingham M et al. Left ventricular
sarcoidosis: correlation with endo-
histology and molecular pathology.
ventricular dysplasia: diagnostic and prognostic value of cardiac MRI
289. Weatherall DJ. Anemia as a World Health Problem. Oxford
terrorism and 2-dimensional echocardi-
290. Anderson LJ, Bance N, Davis B et al. Reversal of siderotic
cardiomyopathy: a prospective study with cardiac magnetic reso-
291. Jenni R, Oechslin E, Schneider J et al. Echocardiographic and
pathoanatomical characteristics of isolated left ventricular non-
compaction: a step towards classification as a distinct cardiomyo-
292. Sasse-Klaassen S, Gerull B, Oechslin E et al. Isolated noncom-
paction of the left ventricular myocardium in the adult is an autosomal
dominant disorder in the majority of patients. Am J Med Genet
293. Rieder K, Fisher MR, Belic N et al. MR imaging of myocardial
inhibitor therapy on left ventricular myocardial and diastolic
filling in previously untreated hypertensive patients: A cine MRI
clinical spectrum and pathoanatomical changes in the course of viral myocarditis.
effects on the left ventricle during beta-blockade with metoprolol in the
administration of heart failure due to dilated cardiomyopathy and coronary artery
disease using gadolinium enhanced cardiovascular magnetic reso-
297. Doherty NJ, Wyss CA, Oechslin EN et al. Isolated ventricular noncom-
298. McCrehon JA, Moon JC, Prasad SK et al. Stratified multi-echo T2*
heart failure related to dilated cardiomyopathy and coronary artery
disease complications in thalassemia major. Ann N Y Acad Sci
299. Ostgarden JC, Sondra J, Kessler RA et al. Randomised, double-blind,
placebo-controlled trial of human recombinant growth hormone in
300. Groening BA, Nilsson JC, Sondgaard L et al. Antiremodeling
effects on the left ventricle during beta-blockade with metoprolol in the
301. Casolo GC, Poggesi L, Boddi M et al. ECG-gated magnetic resonance
303. McKenna WJ, Thiene G, Nava A et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the
Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyo-
304. Anderson LJ, Bance N, Davis B et al. Reversal of siderotic
cardiomyopathy: a prospective study with cardiac magnetic reso-
305. Anderson LJ, Bance N, Davis B et al. Reversal of siderotic
cardiomyopathy: a prospective study with cardiac magnetic reso-
306. Marie PY, Carteaux JP, Angioi M et al. Detection and prediction of
307. Langer M et al. Regression of left
hypertrophy with exercise and the angiotensin converting enzyme
type I/D polymorphism: A randomised controlled trial with Losar-
308. Anderson LJ, Wonke B, Prescott E et al. Comparison of effects of
oral deferiprone and subcutaneous desferrioxamine on myocardial
iron levels and ventricular function in beta thalassaemia. Lancet
309. Westwood M, Anderson LJ, Firmin DN et al. A single breath-hold
multiecho T2* cardiovascular magnetic resonance technique for
resonance imaging in the differential diagnosis of cardiac amyloi-
312. Massi T, Finck S, Higgins CB. Constrictive pericarditis and restrictive


350. de Roos A, Doornbos J, Luyten PR et al. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment...
Clinical indications for cardiovascular magnetic resonance


388. Shaw LJ, Redberg R. From clinical trials to public health policy: the path from imaging to screening. Am J Cardiol 2001;88:62E–5E.


